MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer

This study explores a new way to treat colon cancer after surgery by using a test called minimal residual disease (MRD) which checks for tiny cancer cells left in the body. The study aims to see if people with early-stage colon cancer can benefit from deferred adjuvant therapy (waiting to start additional treatment) if their MRD test is negative. If the MRD test is positive, more intensive treatment might be needed. Participants will have regular tests every 3 to 6 months and follow-ups for up to 5 years. MRD is detected using circulating tumor DNA (ctDNA), a special blood test that looks for cancer DNA in the blood.

• The study lasts up to 5 years with regular check-ups every 3 to 6 months.
• Participants may be divided into different treatment groups based on MRD results.
• Eligibility requires being between 18-70 years old and having specific stages of colon cancer.